SMARCB1 and synovial sarcoma: Indeed we worry about the inter-rater reliability of the variable “reduced but not absent pattern” of BAF47, we acknowledge that reduced BAF47 immunolabeling has been recognized in a growing number of tumor types [24], and caution that synovial sarcomas can change their BAF47 status upon recurrence [21].